Protara Therapeutics Inc (TARA)

Currency in USD
3.130
+0.030(+0.97%)
Closed·
After Hours
3.1300.000(0.00%)
·
TARA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
TARA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.1003.210
52 wk Range
1.59510.480
Key Statistics
Prev. Close
3.1
Open
3.11
Day's Range
3.1-3.21
52 wk Range
1.595-10.48
Volume
265.83K
Average Volume (3m)
323.59K
1-Year Change
64.74%
Book Value / Share
4.31
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TARA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
22.167
Upside
+608.20%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Protara Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Protara Therapeutics Inc Company Profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Compare TARA to Peers and Sector

Metrics to compare
TARA
Peers
Sector
Relationship
P/E Ratio
−2.7x−3.8x−0.5x
PEG Ratio
−0.05−0.010.00
Price/Book
0.8x2.5x2.6x
Price / LTM Sales
-150.6x3.3x
Upside (Analyst Target)
-196.4%43.4%
Fair Value Upside
Unlock4.3%7.1%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 22.167
(+608.20% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.29 / -0.47
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

TARA Income Statement

People Also Watch

2.9000
SNGX
-11.85%
3.090
MBOT
+5.82%
2.200
SABS
-1.35%
2.390
CRDF
-0.83%
16.900
QBTS
-1.57%

FAQ

What Stock Exchange Does Protara Therapeutics Trade On?

Protara Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Protara Therapeutics?

The stock symbol for Protara Therapeutics is "TARA."

What Is the Protara Therapeutics Market Cap?

As of today, Protara Therapeutics market cap is 120.76M.

What Is Protara Therapeutics's Earnings Per Share (TTM)?

The Protara Therapeutics EPS (TTM) is -1.63.

When Is the Next Protara Therapeutics Earnings Date?

Protara Therapeutics will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is TARA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Protara Therapeutics Stock Split?

Protara Therapeutics has split 1 times.

How Many Employees Does Protara Therapeutics Have?

Protara Therapeutics has 31 employees.

What is the current trading status of Protara Therapeutics (TARA)?

As of 10 Aug 2025, Protara Therapeutics (TARA) is trading at a price of 3.13, with a previous close of 3.10. The stock has fluctuated within a day range of 3.10 to 3.21, while its 52-week range spans from 1.60 to 10.48.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.